Steve Schonfeld’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-19,537
| Closed | -$4.32M | – | 2273 |
|
|
2025
Q4 | $4.32M | Buy |
+19,537
| New | +$3.16M | 0.02% | 595 |
|
|
2025
Q3 | – | Sell |
-63,223
| Closed | -$3.08M | – | 2239 |
|
|
2025
Q2 | $3.08M | Buy |
63,223
+42,099
| +199% | +$1.01M | 0.02% | 769 |
|
|
2025
Q1 | $455K | Sell |
21,124
-28,433
| -57% | -$632K | ﹤0.01% | 1621 |
|
|
2024
Q4 | $1.33M | Buy |
49,557
+30,057
| +154% | +$488K | 0.01% | 1002 |
|
|
2024
Q3 | $210K | Buy |
19,500
+100
| +0.5% | +$1.2K | ﹤0.01% | 1799 |
|
|
2024
Q2 | $232K | Sell |
19,400
-8,200
| -30% | -$112K | ﹤0.01% | 1767 |
|
|
2024
Q1 | $508K | Sell |
27,600
-4,145
| -13% | -$59.5K | ﹤0.01% | 1477 |
|
|
2023
Q4 | $504K | Buy |
31,745
+1,190
| +4% | +$19.1K | ﹤0.01% | 1285 |
|
|
2023
Q3 | $576K | Sell |
30,555
-1,690
| -5% | -$33.2K | ﹤0.01% | 1171 |
|
|
2023
Q2 | $729K | Sell |
32,245
-1,075
| -3% | -$25.3K | 0.01% | 1088 |
|
|
2023
Q1 | $846K | Buy |
+33,320
| New | +$946K | 0.01% | 1014 |
|
|
2022
Q2 | – | Sell |
-545
| Closed | -$9K | – | 2582 |
|
|
2022
Q1 | $9K | Buy |
+545
| New | +$9.24K | ﹤0.01% | 2426 |
|
Steve Schonfeld's CDTX Position: Q1 2026 in Review
Steve Schonfeld sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 19,537 shares — an estimated $4.32M sold.
Steve Schonfeld first reported a position in CDTX in Q1 2022 and held it in 12 quarters. The position peaked at $4.32M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Steve Schonfeld reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Steve Schonfeld sold 19,537 Cidara Therapeutics shares in Q1 2026, an estimated $4.32M.
- Steve Schonfeld first reported a position in Cidara Therapeutics in Q1 2022 and held it in 12 quarters.
- Steve Schonfeld's Cidara Therapeutics position peaked at $4.32M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.